BIO

BIO Net Receivables

$441.80MQuarterly · USD

Period ending:

BIO FY Net ReceivablesUSD
BIO FY Net Receivables1985-12-31: $23.10M1986-12-31: $28.60M1987-12-31: $39.40M1988-12-31: $46.70M1989-12-31: $59.20M1990-12-31: $70.50M1991-12-31: $76.20M1992-12-31: $76.20M1993-12-31: $75.80M1994-12-31: $81.70M1995-12-31: $92.10M1996-12-31: $97.80M1997-12-31: $97.00M1998-12-31: $106.00M1999-12-31: $193.90M2000-12-31: $182.24M2001-12-31: $194.40M2002-12-31: $212.28M2003-12-31: $234.09M2004-12-31: $261.24M2005-12-31: $247.19M2006-12-31: $292.97M2007-12-31: $358.08M2008-12-31: $339.65M2009-12-31: $345.73M2010-12-31: $388.00M2011-12-31: $398.67M2012-12-31: $398.74M2013-12-31: $422.66M2014-12-31: $377.64M2015-12-31: $391.49M2016-12-31: $372.35M2017-12-31: $464.85M2018-12-31: $392.44M2019-12-31: $392.67M2020-12-31: $419.42M2021-12-31: $423.54M2022-12-31: $494.65M2023-12-31: $489.00M2024-12-31: $452.50M2025-12-31: $472.50M$494.65M$0.00
1985-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

BIO net receivables history

Net amount expected from customer receivables. The available annual fiscal periods series contains 41 observations from Dec 31, 1985 to Dec 31, 2025.

Bio-Rad Laboratories, Inc. Class A Common Stock Net Receivables — Annual fiscal periods (USD)
Period endingNet Receivables (USD)
472,500,000
452,500,000
489,000,000
494,645,000
423,537,000
419,424,000
392,672,000
392,443,000
464,847,000
372,348,000
391,485,000
377,640,000
422,660,000
398,739,000
398,674,000
387,996,000
345,734,000
339,653,000
358,076,000
292,970,000
247,192,000
261,243,000
234,085,000
212,282,000
194,400,000
182,242,000
193,900,000
106,000,000
97,000,000
97,800,000
92,100,000
81,700,000
75,800,000
76,200,000
76,200,000
70,500,000
59,200,000
46,700,000
39,400,000
28,600,000
23,100,000

Compare net receivables

All BIO financial metrics · BIO stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.